Ciclosporin in the Treatment of Nephrosis

Meyrier, Alain

doi:10.1159/000168042

Cited by 34 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CS may be considered as a further therapeutic tool for the management of steroid-dependent or multire lapsing patients with MChG. We agree with Meyrier [ 18] that in more difficult cases and/or in the presence of severe steroid toxicity, CS and corticosteroids might be alternated, thus maintaining remission while reducing the side effects of these drugs which may be severe when prolonged monotherapy is used.…”

Section: Commentssupporting

confidence: 65%

See 1 more Smart Citation

Ciclosporin in Minimal-Change Glomerulopathy and in Focal Segmental Glomerular Sclerosis

Ponticelli

Rivolta

1990

Am J Nephrol

View full text Add to dashboard Cite

Results of the available literature and preliminary data of an ongoing multicenter, prospective, randomized Italian trial indicate that ciclosporin (CS), at low doses, may maintain remission of the nephrotic syndrome in most steroid-sensitive patients. In steroid-resistant patients CS may cause either complete or partial remission in about 40% of patients with idiopathic nephrotic syndrome. With doses not exeeding 5 mg/kg/day and careful monitoring of renal and liver function, blood pressure and blood levels, severe side effects can be prevented. Although an extensive use of CS in nephrotic syndrome is still premature, cautious trials may be attempted in patients with steroid toxicity and/or devastating nephrotic syndrome.

show abstract

Section: Commentssupporting

confidence: 65%

“…Renal biopsies were repeated in 16 patients. In 10, no sign of CS-related nephrotoxicity was observed, and in the remaining 6 patients, moderate arteriolopathy or mild interstitial fibrosis with few atro phic tubules was seen [14,18,19].…”

Section: Minimal-change Glomerulopathymentioning

confidence: 99%

Ciclosporin in Minimal-Change Glomerulopathy and in Focal Segmental Glomerular Sclerosis

Ponticelli

Rivolta

1990

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…An arteriovenous fistula for daily hemodialysis was used for the first time by Meyerer and Chevet in one patient for six months (2). Daily punctures of the fistula were uneventful and the patient tolerated treatment very well.…”

Section: Subcutaneous Accessmentioning

confidence: 99%

Blood Access Complications and Longevity with Frequent (Daily) Hemodialysis and with Routine Hemodialysis

Twardowski

1999

Seminars in Dialysis

View full text Add to dashboard Cite

“…The action mechanism of CyA in these conditions is not known, but may involve the following: 1) immunomodulation by T-cell mediated cytokines, resulting in restoration of glomerular basement membrane charge selectivity (6, 16); 2) inhibition of vascular permeability factor (17); or 3) non-specific alteration of renal hemodynamics, resulting in reduction of proteinuria (18). …”

Section: Discussionmentioning

confidence: 99%

Effects of Cyclosporin A Therapy Combined with Steroids and Angiotensin Converting Enzyme Inhibitors on Childhood IgA Nephropathy

et al. 2010

View full text Add to dashboard Cite

To evaluate the effects of cyclosporin A (CyA) on clinical outcome and pathologic changes in children with IgA nephropathy (IgAN), we retrospectively evaluated 14 children (mean age 8.9±2.9 yr; eight males, six females) who were treated with CyA and steroids. The starting dose of CyA was 5 mg/kg per day, and the drug level was maintained at 100-200 ng/mL. The mean CyA level was 183.8±48.3 ng/mL (range 120.7-276.0 ng/mL) and the mean duration of CyA therapy was 10.9±1.9 months (range 8-12 months). After CyA therapy the mean 24 hr urinary protein excretion declined from 107.1±35.1 mg/m2/hr to 7.4±2.4 mg/m2/hr (P<0.001) and serum albumin increased from 3.3±0.6 g/dL to 4.3±0.3 g/dL (P<0.001). At a follow-up biopsy the histological grade of IgAN was improved in seven (50%) of the 14 patients, remained the same in three (21%), and was aggravated in four (29%). Serum creatinine, creatinine clearance, and blood pressure did not differ before and after CyA therapy. Two patients (14%) showed CyA-induced nephrotoxicity at the second biopsy. Our findings indicate that CyA therapy may be effective in reducing proteinuria and regressing renal pathology in a subset of children with IgAN.

show abstract

Ciclosporin in the Treatment of Nephrosis

Cited by 34 publications

References 19 publications

Ciclosporin in Minimal-Change Glomerulopathy and in Focal Segmental Glomerular Sclerosis

Ciclosporin in Minimal-Change Glomerulopathy and in Focal Segmental Glomerular Sclerosis

Blood Access Complications and Longevity with Frequent (Daily) Hemodialysis and with Routine Hemodialysis

Effects of Cyclosporin A Therapy Combined with Steroids and Angiotensin Converting Enzyme Inhibitors on Childhood IgA Nephropathy

Contact Info

Product

Resources

About